天安卓健(00383.HK)中期淨利2165.9萬港元 同比增加約15.5倍
格隆匯8月2日丨天安卓健(00383.HK)公吿,截至2024年6月30日止6個月,集團錄得收入總額8.2億港元,同比增加約7.47%,及錄得公司擁有人應占溢利2165.9萬港元,較2023年上半年公司擁有人應占溢利增加約15.5倍。此乃主要由於(i)隨着中華人民共和國疫情防控措施放寬,經濟及社會活動恢復,醫療分部營運收入增加;(ii)醫用耗材成本減少;(iii)銀行存款利息收入增加;及(iv)中國借貸的融資成本減少,惟部分被(v)醫藥及藥品成本增加;(vi)投資物業公允價值虧損;及(vii)可供出售發展中物業撥備增加所抵銷。每股盈利(基本)為1.99港仙(2023年(經重列):0.17港仙)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.